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Dexamethasone has been a mainstay of anti-myeloma therapy for 20 years. However, it is intensely immunosuppressive
and may limit the efficacy of the immune system to control myeloma, and limit the exciting opportunities to use immune
stimulating drug therapies such as Lenalidomide to maximize the fight against this disease.
There is little doubt that the use of high
dose corticosteroid therapy in the form
of either dexamethasone or prednisolone
when used in combination with either
conventional chemotherapy, such as cyclo-
phosphamide, melphalan or adriamycin,
or, more latterly, novel agents such as
bortezomib or lenalidomide have a major
therapeutic impact in the initial therapy of
multiple myeloma (MM).
1
Malignant plasma cells, in common
with other lymphoid cell subtypes, show
a high level of sensitivity to corticosteroid-
induced apoptosis and therefore these
agents are logical choices to control the
devastating effects of MM.
Over the past ten years, therapeutic
regimens against MM have increasingly
adopted novel non-chemotherapeutic
drugs. Included in this therapeutic shift
have been the immunomodulatory drugs
(IMiDs) thalidomide and its pharmaco-
logical derivatives lenalidomide and poma-
lidomide.
1,2 Immunologically, IMiDs are a
fascinating group of agents which, although
the intracellular mechanisms are still to be
defined, show potent immunostimulatory
activity including enhancement of NK cell
function and T-cell co-simulation.
3,4
However, as part of the clinical trial
development of IMiD therapies, they
have often been given in combination
with high-dose dexamethasone and
compared with control cohorts treated
with either dexamethasone alone or con-
ventional dexamethasone-containing salv-
age chemotherapy.
Given the well-known immunosuppres-
sive effects of high-dose corticosteroids,
our previously published analysis examined
whether the immunostimulatory capacity
of lenalidomide could be maintained in a
clinical setting when co-administered with
dexamethasone.
5 Our correlative study
the cellular immunology of patients with
relapsed or refractory MM treated on a
prospective clinical trial of lenalidomide
15 mg daily for 21 days per 28 day cycle
and dexamethasone 20 mg four days per
week for three weeks of each 28 day cycle
(total per cycle dose = 240 mg). We
identified that the absolute numbers of
NK cells in the peripheral blood through
serial cycles of therapy were well main-
tained or increased. Conversely, we iden-
tified that NK cell cytoxicity as measured
by their ability to lyse K562 targets
progressively declined over the course of
therapy. Similarly, we identified that
both absolute number and percent of
CD4
+ T-cells in the peripheral blood of
patients were substantially suppressed at
enrolment and did not improve despite
patients achieving demonstrable clinical
benefit from lenalidomide and dexametha-
sone therapy.
Our initial clinical investigations lead
to an in vitro dissection of the effects of
lenalidomide alone or in combination
with dexamethasone. We identified that,
as shown by others, Lenalidomide did
enhance NK cell function in vitro when
used alone. However, the presence of even
very small doses of dexamethasone resulted
in complete suppression of NK cell
cytotoxic function.
In order to understand this phenome-
non further, we examined the role of other
lymphocyte subsets in this culture system
and identified that the major immuno-
stimulatory capacity of lenalidomide on
NK cell function was via the lenalidomide-
driven production of IL-2 from CD4
+
T cells. Again when cultured in the
presence of dexamethasone, IL-2 pro-
duction from CD4
+ T cells was com-
pletely prevented despite the addition of
lenalidomide.
We therefore concluded that in a
patient with multiple myeloma who
already has a substantial numerical defect
in CD4
+ T cells, the application of both
lenalidomide and dexamethasone in com-
bination while very effective therapy
against MM, resulted in complete abroga-
tion of the potential immunostimulatory
capacity of lenalidomide. Our in vitro
analyses also identified that the effects
of dexamethasone on CD4
+ T-cell IL-2
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dexamethasone was removed from the
culture system.
The implications of these observations
are clear. The presence of dexamethasone
in vivo will result in substantial suppres-
sion of IMiD-driven NK cell-mediated
immune response against MM. Further-
more, the profound suppression of an
already defective IL-2 response is likely to
blunt any potentially adaptive T-cell
response against MM. This phenomenon
may underline the reasons why, when used
with lenalidomide, high-dose dexametha-
sone resulted in poorer patient survival
compared with low-dose dexamethasone
despite the higher rates of response seen in
the high-dose dexamethasone arm.
6
Further to our initial findings we have
also recently identified that dexamethasone
results in suppressive alterations of NK
cell receptor expression, preventing the
lenalidomide-induced expression of the
critical NK cell activating receptors
NKG2D and NKp46 (unpublished data),
resulting in further abrogation of NK cell
function. Our observations have recently
been confirmed by others, in clinical
observations when dexamethasone was
used at . 160 mg per cycle.
7 We have
recently extended these observations via
our ongoing analysis of the immunology
in patients with newly diagnosed MM
enrolled on a range of lenalidomide and
dexamethasone dose combinations. We
have been able to compare the NK cell
function in patients who have yet to be
exposed to any therapy and following
exposure to either Lenalidomide alone or
Lenalidomide in combination with very
low dose dexamethasone of 60 mg per
cycle. In these comparative analyses we
have found, somewhat reassuringly, that if
the dexamethasone is used at these very
low doses (, 60 mg / cycle) it did not
adversely alter the expression NK cell acti-
vating receptors (except for DNAM-1) in
patients with MM (Fig.1)
8 indicating that
NK cell function may well be preserved
in vivo.
Overall, our findings indicate that the
immunostimulatory capacity of IMiDs
in clinical practice are lost when used
in combination with dexamethasone,
potentially denying patients the full bene-
fits of immunological control of MM.
9
We would conclude that the future
design of clinical trials to examine
immunologically mediated mechanisms
of action must limit the exposure of
patients to immunosuppressive agents
such as corticosteroids and similarly
must incorporate prospectively immuno-
logical biomarkers to ensure that the
intended immuno-stimulatory effects are
actually delivered.
Figure 1. The immune-stimulatory effects of immunomodulatory drugs are inhibited by concurrent corticosteroid administration. Enhancement of
NK cell cytotoxicity by immunomodulatory drugs such as lenalidomide require CD4 T cells as intermediates for the production of IL-2. In the presence of
corticosteroids, which is routinely used in the treatment of multiple myeloma patients, the NK stimulatory effect is completely abrogated via two
mechanisms: (1) suppression of IL-2 production by CD4 T cell; and (2) suppression of the major cytotoxic receptor NKG2D on NK cells. The net result of
lenalidomide and dexamethasone combination therapy is the irreversible suppression of NK cell cytotoxicity and hence reduced immune mediated
responses against myeloma.
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